Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 11, Number 10—October 2005
Research

Methicillin-resistant Staphylococcus aureus, Western Australia

Lynne Dailey*, Geoffrey W. Coombs†, Frances G. O'Brien*, John W. Pearman†, Keryn Christiansen†, Warren B. Grubb*, and Thomas V. Riley‡Comments to Author 
Author affiliations: *Curtin University of Technology, Bentley, Western Australia, Australia; †Royal Perth Hospital, Perth, Western Australia, Australia; ‡The University of Western Australia and Western Australian Centre for Pathology & Medical Research, Nedlands, Western Australia, Australia

Main Article

Table 4

Antimicrobial susceptibility of MRSA isolates reported in Western Australia (% susceptible)*

Antimicrobial drug 1998 (1,440†) 1999 (1,058†) 2000 (311†) 2001 (2,326†) 2002 (2,316†)
Gentamicin 98 95 95 92 95
fusidic acid 87 89 87 89 92
Erythromycin 40 43 39 39 40
Mupirocin 99 99 99 99 98
Vancomycin 100 100 100 100 100
Tetracycline 95 94 94 92 94
Rifampicin 99 100 100 99 99
Ciprofloxacin 89 84 76 76 74
Trimethoprim 93 90 93 90 93
Cotrimoxazole 100 100 100 100 100
Chloramphenicol 98 99 99 99 99
Clindamycin 100 100 100 100 100

*MRSA, methicillin-resistant Staphylococcus aureus.
†Number of organisms tested.

Main Article

Page created: February 22, 2012
Page updated: February 22, 2012
Page reviewed: February 22, 2012
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external